1431 Educators providing Courses in Evesham

chipping campden school

This is an outstanding school (OfSTED 2017) with a long and distinguished history dating back to 1440, and a reputation to match. However, it is also a forward-looking school, striving always to provide the best opportunities for students to achieve their potential in a time of rapid change. Choosing the right school takes time and careful consideration. By choosing Chipping Campden School you can be confident that we will provide a relevant and challenging curriculum to meet your child's developing interests and ambitions. However, education for life is about much more than the academic content of courses, and Chipping Campden School offers a wide range of enriching opportunities to prepare its students for their futures. The school is fortunate to have a charitable foundation which supports the development of the school's facilities. Consequently there has been significant investment over a number of years to ensure that the school environment is one which promotes high quality learning. We are also very proud of the care and support we offer our students. Happy and motivated students will be successful students and so we take our responsibilities here very seriously. Every student is treated as an individual while being developed into an active and positive member of the school community and a global citizen. The school offers a very wide range of extra-curricular activities including sport, music and drama and standards here are also very high. There are always opportunities for students to contribute to the wider life of the school through Student Leadership, peer mentoring and charitable fundraising, for example. Staff here are well-qualified and talented professionals. We are united in our desire to ensure that all students reach their potential. We work collaboratively with parents, partner schools and colleges and external agencies to support individual students in this. This website should provide the answers to most of your questions about the school. However, we are very happy to host personal visits and this will give you the confidence that what we describe is the daily reality of the school.

finesse piano cello

david lloyd worcester

gt personal training

GTPT – Game&Poker&Trips&Token

keep my dog happy

siobhan b

Siobhan Bermingham has been helping to empower thousands of people to step into their greatness, grow their self-confidence and accelerate their success in life, for over a decade. Siobhan shares her message of empowerment and transformational techniques through on-stage speaking events, online trainings, digital products and working privately with clients. Utilising her skills as a Master NLP Practitioner who is also trained in mindset coaching, hypnosis, CBT (Cognitive Behavioural Therapy), psychotherapy, healing and intuition work, Sound Healing Meditation work and as the Lead Coach of Dr Ro’s Communication Mastery System – she empowers others to embrace their Authentic Greatness. Siobhan has coached clients from all walks of life whether they were investors wanting to raise more money, entrepreneurs wanting to attract new business partners, mentors/coaches wanting to expand and maximise their businesses, network-marketers wanting to develop their sales techniques, bankers wanting to communicate with more power and precision in meetings, teachers wanting to adapt their communication styles, public speakers wanting to engage their audiences and create more impact or those wanting to build their self-confidence.

dean hale fitness personal trainer

alderman knight school

Alderman Knight School is a special educational needs school for children aged 4-16 with both moderate and additional learning difficulties and Autistic ...

market2win ltd

pcsk9 education and research forum

Reducing low density lipoprotein (LDL) cholesterol is the priority in managing patients with severe dyslipidaemia (cholesterol abnormality) and at high risk of cardiovascular (CV) death and disability. Yet even when treated with potent statins, many patients fail to achieve LDL-cholesterol targets and therefore their risk of accelerated atherosclerosis and CV death remains high. This problem is particularly critical in patients with familial hypercholesterolaemia (FH) (the most commonly occurring genetic condition in the world). People with FH typically have very high LDL cholesterol levels on treatment, and consequently, are at very high risk of premature and sudden CV death, myocardial infarction and stroke. Additionally, some patients are unable to tolerate statins – particularly at higher doses – and, therefore, do not achieve LDL-cholesterol goals. What is the importance of PCSK9? Discovered in 2003,1 PCSK9 is a protein made by the liver which increases the removal of LDL receptors from the surface of liver cells. These LDL receptors are critically important in removal of serum LDL-cholesterol from the circulation. People with so-called ‘gain of function’ PCSK9 mutations over-express PCSK9, and therefore have very high plasma levels of LDL cholesterol and are at very risk of atherosclerosis and CV mortality and morbidity.2 In contrast, people with so-called ‘loss of function’ PCSK9 mutations, have very LDL cholesterol levels and reduced risk for heart disease.3 What is PCSK9 inhibition? Different approaches to lowering PCSK9 are now licensed. These include fully human monoclonal antibodies (alirocumab, evolocumab) and a small-interfering RNA therapy (inclisiran). Trials show that these PCSK9 inhibitors reduce LDL cholesterol levels by about 50-60 percent - a significantly greater effect than that achieved with currently available therapies – either when given alone or in combination. These LDL cholesterol lowering effects have been consistently across a broad group of patients, including those with familial hypercholesterolaemia in clinical trials.4 Which clinical settings will benefit from the availability of PCSK9 inhibitors? These treatments offer the potential to reduce cardiovascular risk in patients whose clinical needs cannot be satisfied by current therapy. These include: Patients with familial hypercholesterolaemia – an inherited disorder of lipid metabolism with a very high risk of early CV death or morbidity, if not diagnosed or treated early Patients who cannot tolerate statins, who therefore remain at high risk of CV events such as heart attacks and strokes Patients with established heart disease who have not achieved LDL-cholesterol goals despite current therapies